GSK, Sanofi Pasteur partner with Gates Foundation to accelerate vaccine R&D

bill melinda gates foundation sanofi gsk (Marc_Smith

GlaxoSmithKline and Sanofi Pasteur have each announced a partnership with the Bill & Melinda Gates Foundation (BMGF) through the newly created Vaccine Discovery Partnership (VxDP).

The VxDP is a BMGF initiative that aims to drive advances in vaccine R&D through collaboration with vaccine-pharmaceutical companies, biotechnology institutions, NGOs and academia.

The partnership with GSK will focus on research into vaccine thermostability, with one of the first projects focussed on increasing the heat stability of adjuvants. GSK researchers will look at making AS01, the adjuvant used in GSK’s RTS,S malaria vaccine candidate, more heat stable. “Reducing the dependence on the cold chain is critical to the affordable delivery of life-saving vaccines to the children who need them most,” said Trevor Mundel, president of Global Health at BMGF. GSK and BMGF are to invest a combined $1.8 million in early stage research.

READ: 6 Novel Adjuvants in Development

The collaboration between Sanofi Pasteur and BMGF will similarly focus on accelerating vaccine R&D through preclinical and early clinical stages. “These challenging projects would be difficult for any one organization to fund without the Partnership,” said John Shiver, Senior VP of R&D for Sanofi Pasteur.“The Gates Foundation is committed to supporting these pilots while we will contribute matching resources and expertise, as well as commit to guaranteeing that advances will support those who need them most through global access provisions.”

Read more at the Sanofi and GSK press release >

Read more:

Keeping cool: 4 innovations that keep the cold chain intact

If you want to know more about vaccines, and meet innovators, disruptors and influencers from across the vaccine research, development and technology landscape, find out about the World Vaccine Congress, 24-26 March 2014, Washington DC.

Leave a Reply

Your email address will not be published. Required fields are marked *